Skip to main content
. 2022 Aug 16;13:986–1002. doi: 10.18632/oncotarget.28258

Figure 5. SCR PFS and OS in blastic MCL.

Figure 5

(A) Overall survival and (B) progression free survival Kaplan-Meier plots of blastic MCL patients on SCR trial. Gray area represents 95% confidence interval. Ticks in graph represent censored patients lost to follow-up.